Melphalan and Glaucoma - a phase IV clinical study of FDA data

Summary:

Glaucoma is reported as a side effect among people who take Melphalan (melphalan), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Velcade, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Glaucoma when taking Melphalan. It is created by eHealthMe based on reports of 20,050 people who have side effects when taking Melphalan from the FDA, and is updated regularly.

What is Melphalan?

Melphalan has active ingredients of melphalan. eHealthMe is studying from 20,052 Melphalan users. Check the latest studies of Melphalan.

What is Glaucoma?

Glaucoma (increased fluid pressure in the eye with vision loss) is found to be associated with 1,233 drugs and 1,656 conditions by eHealthMe. Check the latest studies of Glaucoma.

On Aug, 06, 2026

20,050 people reported to have side effects when taking Melphalan.
Among them, 15 people (0.07%) have Glaucoma.

Among these 15 people:

How long have people been on Melphalan when they have Glaucoma? *

What is the gender of people who have Glaucoma when taking Melphalan? *

female: 55.56 %
male: 44.44 %

What is the age of people who have Glaucoma when taking Melphalan? *

What are other drugs people take besides Melphalan? *

What are other side effects people have besides Glaucoma? *

Intervertebral Disc Degeneration (spinal disc degeneration): 6 people, 40.00%
Osteonecrosis Of Jaw (death of bone of jaw): 6 people, 40.00%
Back Pain: 6 people, 40.00%
Stress And Anxiety: 6 people, 40.00%
Pain: 5 people, 33.33%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 5 people, 33.33%
Joint Pain: 5 people, 33.33%
Dyspnea (difficult or laboured breathing): 5 people, 33.33%
Osteoarthritis (a joint disease caused by cartilage loss in a joint): 5 people, 33.33%
Osteosclerosis (an elevation in bone density): 5 people, 33.33%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 8 people, 53.33%
Retinoblastoma (tumour of retina): 4 people, 26.67%
Pain: 2 people, 13.33%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 13.33%
Haematopoietic Stem Cell Mobilisation: 1 person, 6.67%
Arrhythmias (irregular heartbeat): 1 person, 6.67%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 6.67%
Back Pain: 1 person, 6.67%
Depression: 1 person, 6.67%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Melphalan and have Glaucoma?

- Check whether Glaucoma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Melphalan:

Melphalan (20,052 reports)

Glaucoma treatments and more:

Glaucoma (61,927 reports)

Browse all side effects of Melphalan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Glaucoma:

Glaucoma (1,233 drugs)

Browse all the conditions that are associated with Glaucoma:

Glaucoma (1,656 conditions)

Related publications that referenced our studies

Hu CY, Lee BJ, Cheng HF, Wang CY, "Acetazolamide-related life-threatening hypophosphatemia in a glaucoma patient", Journal of glaucoma, 2015 Apr .
Hu CY, Lee BJ, Cheng HF, Wang CY, "Acetazolamide-related life-threatening hypophosphatemia in a glaucoma patient", Journal of glaucoma, 2015 Apr .

How the study uses the data?

The study uses data from the FDA. It is based on melphalan (the active ingredients of Melphalan) and Melphalan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.